In the last 12 months, insiders at GENELUX Corp ($GNLX) filed 162 transactions with the SEC: 18 open-market purchases totaling $0 and 56 sales totaling $2,410,063. Net insider sentiment: net selling.
GENELUX Corp operates in the Pharmaceutical preparations industry (Life sciences sector).
Most Active Insiders
- Szalay Aladar (Not found) — 24 transactions totaling $2,024,074
- Zindrick Thomas (President and CEO) — 22 transactions totaling $139,966
- Thomas John (Director) — 4 transactions totaling $78,965
- Yu Yong (VP, Clinical Trial Operations) — 9 transactions totaling $30,811
- Cappello Joseph (VP, Pharmaceutical Development) — 7 transactions totaling $28,574
View all SEC Filings for GENELUX Corp (GNLX).
Set Up your own filters →Recent Insider Transactions
| Transaction Date | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|
| March 24, 2026 | Zindrick Thomas | President and CEO | S | Common Stock | 3582 | $2.42 | 534,849.0000 | 38,051,771 | 0.67% | 0.01% |
| March 24, 2026 | Cappello Joseph | Chief Technical Officer | S | Common Stock | 906 | $2.42 | 155,154.0000 | 38,051,771 | 0.58% | 0.00% |
| March 24, 2026 | Yu Yong | SVP, Clinical Development | S | Common Stock | 906 | $2.42 | 144,938.0000 | 38,051,771 | 0.62% | 0.00% |
| March 25, 2026 | Smalling Ralph | Head of Regulatory | S | Common Stock | 240 | $2.51 | 68,073.0000 | 38,051,771 | 0.35% | 0.00% |
| March 24, 2026 | Smalling Ralph | Head of Regulatory | S | Common Stock | 345 | $2.42 | 68,313.0000 | 38,051,771 | 0.50% | 0.00% |
| March 2, 2026 | Thomas John | Director | S | Common Stock | 10000 | $2.90 | 482,784.0000 | 38,051,771 | 2.03% | 0.03% |
| Jan. 2, 2026 | Litten Jason | Chief Medical Officer | A | Stock Option (Right to Buy) | 275000 | $0.00 | 275,000.0000 | 38,051,771 | 9999.99% | 0.72% |
| Nov. 17, 2025 | Zindrick Thomas | President and CEO | S | Common Stock | 4509 | $5.37 | 538,431.0000 | 38,051,771 | 0.83% | 0.01% |
| Nov. 17, 2025 | Yu Yong | SVP, Clinical Development | S | Common Stock | 973 | $5.37 | 145,844.0000 | 38,051,771 | 0.66% | 0.00% |
| Aug. 21, 2025 | Cappello Joseph | Chief Technical Officer | S | Common Stock | 1270 | $3.33 | 158,496.0000 | 34,604,296 | 0.79% | 0.00% |
| Aug. 21, 2025 | Cappello Joseph | Chief Technical Officer | S | Common Stock | 1463 | $3.36 | 157,033.0000 | 34,604,296 | 0.92% | 0.00% |
| Nov. 17, 2025 | Cappello Joseph | Chief Technical Officer | S | Common Stock | 973 | $5.37 | 156,060.0000 | 38,051,771 | 0.62% | 0.00% |
| Aug. 21, 2025 | Zindrick Thomas | President and CEO | S | Common Stock | 12673 | $3.33 | 542,940.0000 | 34,604,296 | 2.28% | 0.04% |
| Aug. 21, 2025 | Yu Yong | SVP, Clinical Development | S | Common Stock | 3219 | $3.36 | 146,817.0000 | 34,604,296 | 2.15% | 0.01% |
| Sept. 3, 2025 | Smalling Ralph | Head of Regulatory | S | Common Stock | 580 | $3.36 | 69,166.0000 | 34,604,296 | 0.83% | 0.00% |
| Nov. 17, 2025 | Smalling Ralph | Head of Regulatory | S | Common Stock | 343 | $5.37 | 68,823.0000 | 38,051,771 | 0.50% | 0.00% |
| Dec. 5, 2025 | Smalling Ralph | Head of Regulatory | S | Common Stock | 165 | $4.69 | 68,658.0000 | 38,051,771 | 0.24% | 0.00% |
| Aug. 21, 2025 | Smalling Ralph | Head of Regulatory | S | Common Stock | 1244 | $3.36 | 69,746.0000 | 34,604,296 | 1.75% | 0.00% |
| Dec. 1, 2025 | Thomas John | Director | S | Common Stock | 10000 | $5.00 | 492,784.0000 | 38,051,771 | 1.99% | 0.03% |
| Sept. 1, 2025 | Smalling Ralph | Head of Regulatory | A | Common Stock | 10000 | $0.00 | 70,990.0000 | 34,604,296 | 16.40% | 0.03% |
| Sept. 1, 2025 | Yu Yong | SVP, Clinical Development | D | Stock Option (Right to Buy) | 65000 | $0.00 | 0.0000 | 34,604,296 | 100.00% | 0.19% |
| Sept. 1, 2025 | Yu Yong | SVP, Clinical Development | A | Stock Option (Right to Buy) | 207652 | $0.00 | 207,652.0000 | 34,604,296 | 9999.99% | 0.60% |
| Sept. 1, 2025 | Yu Yong | SVP, Clinical Development | D | Stock Option (Right to Buy) | 207652 | $0.00 | 0.0000 | 34,604,296 | 100.00% | 0.60% |
| Sept. 1, 2025 | Zindrick Thomas | President and CEO | A | Stock Option (Right to Buy) | 250000 | $0.00 | 250,000.0000 | 34,604,296 | 9999.99% | 0.72% |
| Sept. 1, 2025 | Zindrick Thomas | President and CEO | D | Stock Option (Right to Buy) | 250000 | $0.00 | 0.0000 | 34,604,296 | 100.00% | 0.72% |
| Sept. 1, 2025 | Zindrick Thomas | President and CEO | A | Stock Option (Right to Buy) | 23568 | $0.00 | 23,568.0000 | 34,604,296 | 9999.99% | 0.07% |
| Sept. 1, 2025 | Zindrick Thomas | President and CEO | D | Stock Option (Right to Buy) | 23568 | $0.00 | 0.0000 | 34,604,296 | 100.00% | 0.07% |
| Sept. 1, 2025 | Zindrick Thomas | President and CEO | A | Stock Option (Right to Buy) | 157372 | $0.00 | 157,372.0000 | 34,604,296 | 9999.99% | 0.45% |
| Sept. 1, 2025 | Zindrick Thomas | President and CEO | D | Stock Option (Right to Buy) | 157372 | $0.00 | 0.0000 | 34,604,296 | 100.00% | 0.45% |
| Sept. 1, 2025 | Zindrick Thomas | President and CEO | A | Stock Option (Right to Buy) | 925000 | $0.00 | 925,000.0000 | 34,604,296 | 9999.99% | 2.67% |
| Sept. 1, 2025 | Zindrick Thomas | President and CEO | D | Stock Option (Right to Buy) | 925000 | $0.00 | 0.0000 | 34,604,296 | 100.00% | 2.67% |
| Sept. 1, 2025 | Cappello Joseph | Chief Technical Officer | A | Stock Option (Right to Buy) | 65000 | $0.00 | 65,000.0000 | 34,604,296 | 9999.99% | 0.19% |
| Sept. 1, 2025 | Cappello Joseph | Chief Technical Officer | D | Stock Option (Right to Buy) | 65000 | $0.00 | 0.0000 | 34,604,296 | 100.00% | 0.19% |
| Sept. 1, 2025 | Cappello Joseph | Chief Technical Officer | A | Stock Option (Right to Buy) | 13333 | $0.00 | 13,333.0000 | 34,604,296 | 9999.99% | 0.04% |
| Sept. 1, 2025 | Cappello Joseph | Chief Technical Officer | D | Stock Option (Right to Buy) | 13333 | $0.00 | 0.0000 | 34,604,296 | 100.00% | 0.04% |
| Sept. 1, 2025 | Cappello Joseph | Chief Technical Officer | A | Stock Option (Right to Buy) | 80000 | $0.00 | 80,000.0000 | 34,604,296 | 9999.99% | 0.23% |
| Sept. 1, 2025 | Cappello Joseph | Chief Technical Officer | D | Stock Option (Right to Buy) | 80000 | $0.00 | 0.0000 | 34,604,296 | 100.00% | 0.23% |
| Sept. 1, 2025 | Cappello Joseph | Chief Technical Officer | A | Stock Option (Right to Buy) | 16666 | $0.00 | 16,666.0000 | 34,604,296 | 9999.99% | 0.05% |
| Sept. 1, 2025 | Cappello Joseph | Chief Technical Officer | D | Stock Option (Right to Buy) | 16666 | $0.00 | 0.0000 | 34,604,296 | 100.00% | 0.05% |
| Sept. 1, 2025 | Smalling Ralph | Head of Regulatory | A | Stock Option (Right to Buy) | 8333 | $0.00 | 8,333.0000 | 34,604,296 | 9999.99% | 0.02% |
| Sept. 1, 2025 | Smalling Ralph | Head of Regulatory | D | Stock Option (Right to Buy) | 8333 | $0.00 | 0.0000 | 34,604,296 | 100.00% | 0.02% |
| Sept. 1, 2025 | Yu Yong | SVP, Clinical Development | A | Stock Option (Right to Buy) | 65000 | $0.00 | 65,000.0000 | 34,604,296 | 9999.99% | 0.19% |
| Aug. 27, 2025 | Smither John W | Director | A | Common Stock | 22283 | $0.00 | 74,994.0000 | 34,604,296 | 42.27% | 0.06% |
| Aug. 27, 2025 | Smalling Ralph | Head of Regulatory | A | Stock Option (Right to Buy) | 34770 | $0.00 | 34,770.0000 | 34,604,296 | 9999.99% | 0.10% |
| Aug. 27, 2025 | Thomas John | Director | A | Common Stock | 22283 | $0.00 | 502,784.0000 | 34,604,296 | 4.64% | 0.06% |
| Aug. 27, 2025 | Thomas John | Director | A | Stock Option (Right to Buy) | 28576 | $0.00 | 28,576.0000 | 34,604,296 | 9999.99% | 0.08% |
| Aug. 27, 2025 | Zindrick Thomas | President and CEO | A | Common Stock | 361200 | $0.00 | 554,161.0000 | 34,604,296 | 187.19% | 1.04% |
| Aug. 27, 2025 | Zindrick Thomas | President and CEO | A | Stock Option (Right to Buy) | 478800 | $0.00 | 478,800.0000 | 34,604,296 | 9999.99% | 1.38% |
| Aug. 27, 2025 | Smalling Ralph | Head of Regulatory | A | Common Stock | 26230 | $0.00 | 60,990.0000 | 34,604,296 | 75.46% | 0.08% |
| Aug. 27, 2025 | Cappello Joseph | Chief Technical Officer | A | Stock Option (Right to Buy) | 142500 | $0.00 | 142,500.0000 | 34,604,296 | 9999.99% | 0.41% |
| Aug. 27, 2025 | Cappello Joseph | Chief Technical Officer | A | Common Stock | 107500 | $0.00 | 159,766.0000 | 34,604,296 | 205.68% | 0.31% |
| Aug. 27, 2025 | Tyree James L | Director | A | Stock Option (Right to Buy) | 28576 | $0.00 | 28,576.0000 | 34,604,296 | 9999.99% | 0.08% |
| Aug. 27, 2025 | Tyree James L | Director | A | Common Stock | 22283 | $0.00 | 68,074.0000 | 34,604,296 | 48.66% | 0.06% |
| Aug. 27, 2025 | Mirabelli Mary | Director | A | Stock Option (Right to Buy) | 28576 | $0.00 | 28,576.0000 | 34,604,296 | 9999.99% | 0.08% |
| Aug. 27, 2025 | Mirabelli Mary | Director | A | Common Stock | 22283 | $0.00 | 73,284.0000 | 34,604,296 | 43.69% | 0.06% |
| Aug. 27, 2025 | Yu Yong | SVP, Clinical Development | A | Stock Option (Right to Buy) | 134520 | $0.00 | 134,520.0000 | 34,604,296 | 9999.99% | 0.39% |
| Aug. 27, 2025 | Yu Yong | SVP, Clinical Development | A | Common Stock | 101480 | $0.00 | 150,036.0000 | 34,604,296 | 209.00% | 0.29% |
| Aug. 27, 2025 | Smither John W | Director | A | Stock Option (Right to Buy) | 28576 | $0.00 | 28,576.0000 | 34,604,296 | 9999.99% | 0.08% |
| July 1, 2025 | Groen Eric | General Counsel & Secretary | A | Stock Option (Right to Buy) | 270000 | $0.00 | 270,000.0000 | 34,604,296 | 9999.99% | 0.78% |
| June 6, 2025 | Thomas John | Not found | G | Common Stock | 25000 | $0.00 | 480,501.0000 | 34,604,296 | 4.95% | 0.07% |
| May 12, 2025 | Cappello Joseph | VP, Pharmaceutical Development | S | Common Stock | 4737 | $2.92 | 52,266.0000 | 34,604,296 | 8.31% | 0.01% |
| May 12, 2025 | Smalling Ralph | Head of Regulatory | S | Common Stock | 1259 | $2.92 | 34,760.0000 | 34,604,296 | 3.50% | 0.00% |
| May 12, 2025 | Ryder Sean | General Counsel | S | Common Stock | 4475 | $2.92 | 47,621.0000 | 34,604,296 | 8.59% | 0.01% |
| May 12, 2025 | Zindrick Thomas | President and CEO | S | Common Stock | 10764 | $2.92 | 191,447.0000 | 34,604,296 | 5.32% | 0.03% |
| May 12, 2025 | Yu Yong | VP, Clinical Trial Operations | S | Common Stock | 5579 | $2.92 | 47,640.0000 | 34,604,296 | 10.48% | 0.02% |
| March 14, 2025 | Cappello Joseph | VP, Pharmaceutical Development | A | Common Stock | 13350 | $0.00 | 57,003.0000 | 0 | 30.58% | 0.00% |
| March 14, 2025 | Zindrick Thomas | President and CEO | A | Common Stock | 30339 | $0.00 | 202,211.0000 | 0 | 17.65% | 0.00% |
| March 14, 2025 | Yu Yong | VP, Clinical Trial Operations | A | Common Stock | 13350 | $0.00 | 53,219.0000 | 0 | 33.48% | 0.00% |
| March 14, 2025 | Ryder Sean | General Counsel | A | Common Stock | 10708 | $0.00 | 52,096.0000 | 0 | 25.87% | 0.00% |
| March 14, 2025 | Smalling Ralph | Head of Regulatory | A | Common Stock | 4172 | $0.00 | 36,019.0000 | 0 | 13.10% | 0.00% |
| Jan. 31, 2025 | Pulisic Matthew | Chief Financial Officer | A | Stock Option (right to buy) | 275000 | $0.00 | 275,000.0000 | 0 | 9999.99% | 0.00% |
| Aug. 1, 2024 | Mirabelli Mary | Not found | A | Stock Option Right to Buy) | 50469 | $0.00 | 50,469.0000 | 0 | 9999.99% | 0.00% |
| Aug. 1, 2024 | Thomas John | Not found | A | Stock Option Right to Buy) | 50469 | $0.00 | 50,469.0000 | 0 | 9999.99% | 0.00% |
| Aug. 1, 2024 | Tyree James L | Not found | A | Stock Option Right to Buy) | 50469 | $0.00 | 50,469.0000 | 0 | 9999.99% | 0.00% |
| Aug. 1, 2024 | Smither John W | Not found | A | Stock Option Right to Buy) | 50469 | $0.00 | 50,469.0000 | 0 | 9999.99% | 0.00% |
| Dec. 30, 2024 | Tyree James L | Not found | S | Common Stock | 3460 | $2.46 | 45,791.0000 | 0 | 7.03% | 0.00% |
| Dec. 18, 2024 | Yu Yong | VP, Clinical Trial Operations | A | Common Stock | 29000 | $0.00 | 39,869.0000 | 0 | 266.81% | 0.00% |
| Dec. 18, 2024 | Smalling Ralph | Head of Regulatory | A | Common Stock | 15525 | $0.00 | 31,847.0000 | 0 | 95.12% | 0.00% |
| Dec. 18, 2024 | Smalling Ralph | Head of Regulatory | A | Stock Option (right to buy) | 21100 | $0.00 | 21,100.0000 | 0 | 9999.99% | 0.00% |
| Dec. 18, 2024 | Ryder Sean | General Counsel | A | Common Stock | 22000 | $0.00 | 41,388.0000 | 0 | 113.47% | 0.00% |
| Dec. 18, 2024 | Ryder Sean | General Counsel | A | Stock Option (right to buy) | 30000 | $0.00 | 30,000.0000 | 0 | 9999.99% | 0.00% |
| Dec. 18, 2024 | Yu Yong | VP, Clinical Trial Operations | A | Stock Option (right to buy) | 39000 | $0.00 | 39,000.0000 | 0 | 9999.99% | 0.00% |
| Dec. 18, 2024 | Cappello Joseph | VP, Pharmaceutical Development | A | Common Stock | 29000 | $0.00 | 43,653.0000 | 0 | 197.91% | 0.00% |
| Dec. 18, 2024 | Cappello Joseph | VP, Pharmaceutical Development | A | Stock Option (right to buy) | 39000 | $0.00 | 39,000.0000 | 0 | 9999.99% | 0.00% |
| Dec. 18, 2024 | Zak Lourie S. | Chief Financial Officer | A | Common Stock | 41650 | $0.00 | 82,452.0000 | 0 | 102.08% | 0.00% |
| Dec. 18, 2024 | Zak Lourie S. | Chief Financial Officer | A | Stock Option (right to buy) | 56525 | $0.00 | 56,525.0000 | 0 | 9999.99% | 0.00% |
| Dec. 18, 2024 | Zindrick Thomas | President and CEO | A | Common Stock | 134500 | $0.00 | 171,872.0000 | 0 | 359.90% | 0.00% |
| Dec. 18, 2024 | Zindrick Thomas | President and CEO | A | Stock Option (right to buy) | 183000 | $0.00 | 183,000.0000 | 0 | 9999.99% | 0.00% |
| Dec. 16, 2024 | Zindrick Thomas | President and CEO | S | Common Stock | 14315 | $2.34 | 37,372.0000 | 0 | 27.70% | 0.00% |
| Dec. 16, 2024 | Cappello Joseph | VP, Pharmaceutical Development | S | Common Stock | 6300 | $2.34 | 14,653.0000 | 0 | 30.07% | 0.00% |
| Dec. 16, 2024 | Smalling Ralph | Head of Regulatory | S | Common Stock | 2510 | $2.34 | 16,322.0000 | 0 | 13.33% | 0.00% |
| Dec. 16, 2024 | Zak Lourie S. | Chief Financial Officer | S | Common Stock | 2103 | $2.34 | 40,802.0000 | 0 | 4.90% | 0.00% |
| Oct. 18, 2024 | Scigalla Paul | Chief Medical Officer | A | Stock Option (right to buy) | 16666 | $0.00 | 16,666.0000 | 0 | 9999.99% | 0.00% |
| Oct. 18, 2024 | Scigalla Paul | Chief Medical Officer | A | Stock Option (right to buy) | 16666 | $0.00 | 16,666.0000 | 0 | 9999.99% | 0.00% |
| Sept. 13, 2024 | Szalay Aladar | Not found | S | Common Stock | 33080 | $2.57 | 3,413,581.0000 | 0 | 0.96% | 0.00% |
| Sept. 12, 2024 | Szalay Aladar | Not found | S | Common Stock | 31777 | $2.73 | 3,446,661.0000 | 0 | 0.91% | 0.00% |
| Sept. 11, 2024 | Tyree James L | Not found | S | Common Stock | 1730 | $2.60 | 47,521.0000 | 0 | 3.51% | 0.00% |
| Sept. 10, 2024 | Szalay Aladar | Not found | S | Common Stock | 20384 | $2.51 | 3,509,814.0000 | 0 | 0.58% | 0.00% |
| Sept. 11, 2024 | Szalay Aladar | Not found | S | Common Stock | 31376 | $2.62 | 3,478,438.0000 | 0 | 0.89% | 0.00% |
| Sept. 9, 2024 | Szalay Aladar | Not found | S | Common Stock | 23383 | $2.70 | 3,530,198.0000 | 0 | 0.66% | 0.00% |
| Sept. 3, 2024 | Szalay Aladar | Not found | S | Common Stock | 42818 | $2.09 | 3,553,581.0000 | 0 | 1.19% | 0.00% |
| Aug. 28, 2024 | Szalay Aladar | Not found | S | Common Stock | 15918 | $2.05 | 3,846,033.0000 | 0 | 0.41% | 0.00% |
| Aug. 29, 2024 | Szalay Aladar | Not found | S | Common Stock | 107045 | $1.98 | 3,738,988.0000 | 0 | 2.78% | 0.00% |
| Aug. 30, 2024 | Szalay Aladar | Not found | S | Common Stock | 142589 | $2.17 | 3,596,399.0000 | 0 | 3.81% | 0.00% |
| Aug. 23, 2024 | Szalay Aladar | Not found | S | Common Stock | 40000 | $2.29 | 3,913,581.0000 | 0 | 1.01% | 0.00% |
| Aug. 27, 2024 | Szalay Aladar | Not found | S | Common Stock | 51630 | $2.11 | 3,861,951.0000 | 0 | 1.32% | 0.00% |
| Aug. 1, 2024 | Tyree James L | Not found | A | Stock Option Right to Buy) | 50469 | $0.00 | 50,469.0000 | 0 | 9999.99% | 0.00% |
| Aug. 1, 2024 | Mirabelli Mary | Not found | A | Common Stock | 39541 | $0.00 | 52,001.0000 | 0 | 317.34% | 0.00% |
| Aug. 1, 2024 | Mirabelli Mary | Not found | A | Stock Option Right to Buy) | 50469 | $0.00 | 50,469.0000 | 0 | 9999.99% | 0.00% |
| Aug. 1, 2024 | Thomas John | Not found | A | Common Stock | 39541 | $0.00 | 505,501.0000 | 0 | 8.49% | 0.00% |
| Aug. 1, 2024 | Thomas John | Not found | A | Stock Option Right to Buy) | 50469 | $0.00 | 50,469.0000 | 0 | 9999.99% | 0.00% |
| Aug. 1, 2024 | Smither John W | Not found | A | Common Stock | 39541 | $0.00 | 52,711.0000 | 0 | 300.24% | 0.00% |
| Aug. 1, 2024 | Smither John W | Not found | A | Stock Option Right to Buy) | 50469 | $0.00 | 50,469.0000 | 0 | 9999.99% | 0.00% |
| Aug. 1, 2024 | Tyree James L | Not found | A | Common Stock | 39541 | $0.00 | 49,251.0000 | 0 | 407.22% | 0.00% |
| Feb. 19, 2024 | Yu Yong | VP, Clinical Trial Operations | A | Common Stock | 3661 | $0.00 | 6,161.0000 | 0 | 146.44% | 0.00% |
| June 24, 2024 | Jewett Caroline | Head of Quality | S | Common Stock | 4961 | $2.12 | 16,174.0000 | 0 | 23.47% | 0.00% |
| March 14, 2024 | Jewett Caroline | Head of Quality | A | Common Stock | 3612 | $0.00 | 25,890.0000 | 0 | 16.21% | 0.00% |
| Feb. 19, 2024 | Jewett Caroline | Head of Quality | A | Common Stock | 1143 | $0.00 | 22,278.0000 | 0 | 5.41% | 0.00% |
| June 24, 2024 | Ryder Sean | General Counsel | S | Common Stock | 5496 | $2.12 | 19,388.0000 | 0 | 22.09% | 0.00% |
| June 24, 2024 | Yu Yong | VP, Clinical Trial Operations | S | Common Stock | 6849 | $2.12 | 10,869.0000 | 0 | 38.66% | 0.00% |
| March 14, 2024 | Yu Yong | VP, Clinical Trial Operations | A | Common Stock | 11557 | $0.00 | 17,718.0000 | 0 | 187.58% | 0.00% |
| March 14, 2024 | Cappello Joseph | VP, Pharmaceutical Development | A | Common Stock | 11557 | $0.00 | 20,953.0000 | 0 | 123.00% | 0.00% |
| Feb. 19, 2024 | Cappello Joseph | VP, Pharmaceutical Development | A | Common Stock | 3661 | $0.00 | 9,396.0000 | 0 | 63.84% | 0.00% |
| March 14, 2024 | Smalling Ralph | Head of Regulatory | A | Common Stock | 2107 | $0.00 | 18,144.0000 | 0 | 13.14% | 0.00% |
| Feb. 19, 2024 | Smalling Ralph | Head of Regulatory | A | Common Stock | 616 | $0.00 | 13,931.0000 | 0 | 4.63% | 0.00% |
| March 14, 2024 | Zak Lourie S. | Chief Financial Officer | A | Common Stock | 3852 | $0.00 | 38,428.0000 | 0 | 11.14% | 0.00% |
| Feb. 19, 2024 | Zak Lourie S. | Chief Financial Officer | A | Common Stock | 1220 | $0.00 | 32,470.0000 | 0 | 3.90% | 0.00% |
| March 14, 2024 | Zindrick Thomas | President and CEO | A | Common Stock | 26264 | $0.00 | 50,207.0000 | 0 | 109.69% | 0.00% |
| Feb. 19, 2024 | Zindrick Thomas | President and CEO | A | Common Stock | 8320 | $0.00 | 22,971.0000 | 0 | 56.79% | 0.00% |
| March 14, 2024 | Ryder Sean | General Counsel | A | Common Stock | 9270 | $0.00 | 22,778.0000 | 0 | 68.63% | 0.00% |
| Feb. 19, 2024 | Ryder Sean | General Counsel | A | Common Stock | 2936 | $0.00 | 13,508.0000 | 0 | 27.77% | 0.00% |
| May 29, 2024 | Tyree James L | Not found | P | Common Stock | 6250 | $0.00 | 9,710.0000 | 0 | 180.64% | 0.00% |
| May 29, 2024 | Zak Lourie S. | Chief Financial Officer | P | Common Stock Warrant (Right to Buy) | 31250 | $0.00 | 31,250.0000 | 0 | 9999.99% | 0.00% |
| May 29, 2024 | Zak Lourie S. | Chief Financial Officer | P | Common Stock | 31250 | $0.00 | 31,250.0000 | 0 | 9999.99% | 0.00% |
| May 29, 2024 | Thomas John | Not found | P | Common Stock | 2500 | $0.00 | 465,960.0000 | 0 | 0.54% | 0.00% |
| May 29, 2024 | Thomas John | Not found | P | Common Stock Warrant (Right to Buy) | 2500 | $0.00 | 2,500.0000 | 0 | 9999.99% | 0.00% |
| May 29, 2024 | Mirabelli Mary | Not found | P | Common Stock | 8000 | $0.00 | 12,460.0000 | 0 | 179.37% | 0.00% |
| May 29, 2024 | Mirabelli Mary | Not found | P | Common Stock Warrant (Right to Buy) | 8000 | $0.00 | 8,000.0000 | 0 | 9999.99% | 0.00% |
| May 29, 2024 | Yu Yong | VP, Clinical Trial Operations | P | Common Stock | 2500 | $0.00 | 2,500.0000 | 0 | 9999.99% | 0.00% |
| May 29, 2024 | Yu Yong | VP, Clinical Trial Operations | P | Common Stock Warrant (Right to Buy) | 2500 | $0.00 | 2,500.0000 | 0 | 9999.99% | 0.00% |
| May 29, 2024 | Zindrick Thomas | President and CEO | P | Common Stock | 200000 | $0.00 | 214,651.0000 | 0 | 1365.10% | 0.00% |
| May 29, 2024 | Zindrick Thomas | President and CEO | P | Common Stock Warrant (Right to Buy) | 200000 | $0.00 | 200,000.0000 | 0 | 9999.99% | 0.00% |
| May 29, 2024 | Smalling Ralph | Head of Regulatory | P | Common Stock | 1250 | $0.00 | 13,315.0000 | 0 | 10.36% | 0.00% |
| May 29, 2024 | Smalling Ralph | Head of Regulatory | P | Common Stock Warrant (Right to Buy) | 1250 | $0.00 | 1,250.0000 | 0 | 9999.99% | 0.00% |
| May 29, 2024 | Ryder Sean | General Counsel | P | Common Stock | 10000 | $0.00 | 10,572.0000 | 0 | 1748.25% | 0.00% |
| May 29, 2024 | Ryder Sean | General Counsel | P | Common Stock Warrant (Right to Buy) | 10000 | $0.00 | 10,000.0000 | 0 | 9999.99% | 0.00% |
| May 29, 2024 | Smither John W | Not found | P | Common Stock Warrant (Right to Buy) | 6250 | $0.00 | 6,250.0000 | 0 | 9999.99% | 0.00% |
| May 29, 2024 | Smither John W | Not found | P | Common Stock | 6250 | $0.00 | 13,170.0000 | 0 | 90.32% | 0.00% |
| May 29, 2024 | Tyree James L | Not found | P | Common Stock Warrant (Right to Buy) | 6250 | $0.00 | 6,250.0000 | 0 | 9999.99% | 0.00% |
| May 14, 2024 | Szalay Aladar | Not found | S | Common Stock | 15426 | $3.58 | 3,970,675.0000 | 0 | 0.39% | 0.00% |
| May 13, 2024 | Szalay Aladar | Not found | S | Common Stock | 3446 | $3.62 | 3,986,101.0000 | 0 | 0.09% | 0.00% |
| May 15, 2024 | Szalay Aladar | Not found | S | Common Stock | 17094 | $3.66 | 3,953,581.0000 | 0 | 0.43% | 0.00% |
| May 7, 2024 | Szalay Aladar | Not found | S | Common Stock | 6025 | $3.67 | 4,003,466.0000 | 0 | 0.15% | 0.00% |
| May 8, 2024 | Szalay Aladar | Not found | S | Common Stock | 13919 | $3.82 | 3,989,547.0000 | 0 | 0.35% | 0.00% |
| April 30, 2024 | Szalay Aladar | Not found | S | Common Stock | 20535 | $3.12 | 4,042,552.0000 | 0 | 0.51% | 0.00% |
| April 29, 2024 | Szalay Aladar | Not found | S | Common Stock | 6403 | $3.25 | 4,063,087.0000 | 0 | 0.16% | 0.00% |
| May 1, 2024 | Szalay Aladar | Not found | S | Common Stock | 33061 | $3.30 | 4,009,491.0000 | 0 | 0.82% | 0.00% |
| April 24, 2024 | Szalay Aladar | Not found | S | Common Stock | 8064 | $3.50 | 4,069,490.0000 | 0 | 0.20% | 0.00% |
| April 22, 2024 | Szalay Aladar | Not found | S | Common Stock | 14331 | $3.53 | 4,099,554.0000 | 0 | 0.35% | 0.00% |
| April 23, 2024 | Szalay Aladar | Not found | S | Common Stock | 22000 | $3.49 | 4,077,554.0000 | 0 | 0.54% | 0.00% |
| April 16, 2024 | Szalay Aladar | Not found | S | Common Stock | 48683 | $3.53 | 4,136,622.0000 | 0 | 1.16% | 0.00% |
| April 17, 2024 | Szalay Aladar | Not found | S | Common Stock | 22737 | $3.71 | 4,113,885.0000 | 0 | 0.55% | 0.00% |